San Diego’s Heron Therapeutics said Thursday it has received marketing approval for a drug to prevent chemotherapy-associated nausea and vomiting.
The injectable drug, Cinvanti, is the second such drug for Heron Therapeutics; the first is Sustol.
The drugs work by different mechanisms to inhibit nausea and vomiting, so they don't duplicate each other. This makes them a good fit for Heron, said CEO Barry Quart in a statement.
Cinvanti sales are expected to begin in January of next year, Quart said.
Cinvanti was approved by the U.S. Food and Drug Administration on the basis of clinical studies demonstrating it was biologically equivalent to a previously approved drug, Emend IV, generically called fosaprepitant dimeglumine.
Unlike other drugs in its chemical class, Cinvanti is free of polysorbate 80, which has been linked to allergic reactions, Heron said.